Beijing Beilu Pharmaceutical Co., Ltd. (300016) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Beilu Pharmaceutical Co., Ltd.

Why is Beijing Beilu Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 6.86% and Operating profit at -17.73% over the last 5 years

The company declared positive results in Mar'25 after flat results in Dec'24

PRE-TAX PROFIT(Q) At CNY 16.18 MM has Grown at 442.82%
OPERATING CASH FLOW(Y) Highest at CNY 183.35 MM
NET SALES(9M) At CNY 781.9 MM has Grown at 19.76%

With ROE of 0.93%, it has a expensive valuation with a 2.08 Price to Book Value

Over the past year, while the stock has generated a return of 13.89%, its profits have risen by 134.6% ; the PEG ratio of the company is 1.7
At the current price, the company has a high dividend yield of 0.7

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Beilu Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Beilu Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Beilu Pharmaceutical Co., Ltd.

13.34%

1.59

56.07%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.86%

EBIT Growth (5y)

-17.73%

EBIT to Interest (avg)

2.51

Debt to EBITDA (avg)

0.83

Net Debt to Equity (avg)

0.16

Sales to Capital Employed (avg)

0.35

Tax Ratio

100.00%

Dividend Payout Ratio

179.86%

Pledged Shares

Institutional Holding

ROCE (avg)

3.85%

ROE (avg)

2.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

222

Industry P/E

Price to Book Value

2.08

EV to EBIT

72.30

EV to EBITDA

24.37

EV to Capital Employed

1.90

EV to Sales

3.57

PEG Ratio

1.65

Dividend Yield

0.70%

ROCE (Latest)

2.63%

ROE (Latest)

0.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 16.18 MM has Grown at 442.82%

OPERATING CASH FLOW(Y)

Highest at CNY 183.35 MM

NET SALES(9M)

At CNY 781.9 MM has Grown at 19.76%

ROCE(HY)

Highest at 1%

INVENTORY TURNOVER RATIO(HY)

Highest at 1.99%

NET PROFIT(9M)

Higher at CNY 11.61 MM

EPS(Q)

Highest at CNY 0.03

-9What is not working for the Company

INTEREST(9M)

At CNY 44.98 MM has Grown at 8.35%

DEBT-EQUITY RATIO (HY)

Highest at 15.76 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.07%

RAW MATERIAL COST(Y)

Grown by 12.4% (YoY

Here's what is working for Beijing Beilu Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 16.18 MM has Grown at 442.82%

over average net sales of the previous four periods of CNY 2.98 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 14.46 MM has Grown at 147.92%

over average net sales of the previous four periods of CNY 5.83 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Inventory Turnover Ratio

Highest at 1.99% and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Operating Cash Flow

Highest at CNY 183.35 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 279.03 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Profit

Highest at CNY 14.46 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.03

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Here's what is not working for Beijing Beilu Pharmaceutical Co., Ltd.

Interest

At CNY 29.12 MM has Grown at 6.91%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 15.76 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 6.07% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 12.4% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales